The information in this section is intended for visitors outside the United States.
At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development effort is the largest it has ever been, with more than 200 active clinical studies evaluating compounds with potential to become next-generation therapies. Collaboration with other companies, universities and medical research institutions enhance our ability to discover and develop innovative new medicines.
Our goal is to improve HIV care by developing new single tablet regimens – with one pill once a day, eligible patients take all of their medication in each dose, which increases dosing convenience and potentially reduces the risk of drug resistance. Gilead scientists are also engaged in early-stage research to identify novel therapeutic agents that may help eradicate HIV infection.
Our liver disease research focuses on new treatment options for chronic hepatitis B and C. For hepatitis B, we continue to research approaches to increase cure rates, including oral medicines and therapeutic vaccines. For hepatitis C, we are working to develop an all-oral regimen that results in higher cure rates over a shortened treatment duration compared to today’s standard of care.
A range of clinical studies are ongoing to explore new uses for Ranexa®, currently indicated for the treatment of chronic angina, that can potentially benefit a broader population of patients. We are also working to identify new therapies for cardiovascular disease by exploring the mechanism of action underlying Ranexa – inhibition of the late sodium current.
Gilead is investigating new ways to improve care for people who suffer from potentially life-threatening respiratory disorders. Simtuzumab is being investigated for the potential treatment of idiopathic pulmonary fibrosis, a life-threatening scarring of the lungs that has no known cause. We are also evaluating the potential of a new agent to block the respiratory syncytial virus.
Gilead is making rapid progress in identifying targeted cancer therapies and evaluating them in clinical studies. Idelalisib is a small molecule drug designed to inhibit the PI3K delta signaling pathway that drives certain cancer cell development. Momelotinib is an investigational JAK inhibitor that has shown promise for the treatment of myelofibrosis, a blood disorder. Simtuzumab is the first monoclonal antibody developed to target LOXL2, an enzyme involved in solid tumor growth. Importantly, certain targeted agents may have fewer side effects than conventional treatments such as chemotherapy.